These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28634198)

  • 1. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
    Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection.
    El-Serag HB; Christie IC; Puenpatom A; Castillo D; Kanwal F; Kramer JR
    Aliment Pharmacol Ther; 2019 Jun; 49(11):1442-1447. PubMed ID: 30932218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
    Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
    J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).
    Huang CF; Lai HC; Chen CY; Tseng KC; Kuo HT; Hung CH; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang JF; Dai CY; Chuang WL; Tsai PC; Peng CY; Yu ML
    Am J Gastroenterol; 2020 Aug; 115(8):1226-1235. PubMed ID: 32221162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
    Leone S; Prosperi M; Costarelli S; Nasta P; Maggiolo F; Di Giambenedetto S; Saracino A; Di Pietro M; Gori A
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1511-20. PubMed ID: 27272121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.
    Peveling-Oberhag J; Arcaini L; Bankov K; Zeuzem S; Herrmann E
    J Viral Hepat; 2016 Jul; 23(7):536-44. PubMed ID: 26924533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrahepatic manifestations of hepatitis C among United States male veterans.
    El-Serag HB; Hampel H; Yeh C; Rabeneck L
    Hepatology; 2002 Dec; 36(6):1439-45. PubMed ID: 12447870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States.
    Li J; Zhang T; Gordon SC; Rupp LB; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Lu M;
    J Viral Hepat; 2018 Aug; 25(8):952-958. PubMed ID: 29478263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.
    Younossi Z; Park H; Henry L; Adeyemi A; Stepanova M
    Gastroenterology; 2016 Jun; 150(7):1599-1608. PubMed ID: 26924097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.
    Wiznia LE; Laird ME; Franks AG
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1260-1270. PubMed ID: 28252812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
    Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
    J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy.
    Mazzaro C; Quartuccio L; Adinolfi LE; Roccatello D; Pozzato G; Nevola R; Tonizzo M; Gitto S; Andreone P; Gattei V
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Cacoub P; Desbois AC; Comarmond C; Saadoun D
    Gut; 2018 Nov; 67(11):2025-2034. PubMed ID: 29703790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with pegylated interferon alfa-2a and ribavirin].
    Fabri M; Ruzić M; Lendak D; Preveden T; Fabri I; Petrić V
    Srp Arh Celok Lek; 2013; 141(5-6):320-4. PubMed ID: 23858800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.
    El-Serag HB; Kanwal F; Richardson P; Kramer J
    Hepatology; 2016 Jul; 64(1):130-7. PubMed ID: 26946190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals.
    García-Fraile LJ; García-Buey L; Alonso Cerezo C; Sanz Sanz J; de Los Santos Gil I
    Gastroenterol Hepatol; 2022 Apr; 45(4):249-255. PubMed ID: 34562521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study.
    Cheng YT; Cheng JS; Lin CH; Chen TH; Lee KC; Chang ML
    Clin Microbiol Infect; 2020 Mar; 26(3):366-372. PubMed ID: 31229596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term impact of certain coexisting extrahepatic unisystem and multisystem manifestations on trends in incidence of liver cirrhosis in treatment-naïve patients with chronic hepatitis C: A nested case-control study.
    Wang CH; Ou SF; Tseng YT
    Medicine (Baltimore); 2022 Jul; 101(29):e29697. PubMed ID: 35866797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.